Home » Clinical Trials » Search Clinical Trials
Therapeutic Areas: Pulmonary/Respiratory Diseases
Clinical Trials: Lung Injury
A listing of clinical trials currently looking for volunteers to enroll in Lung Injury studies. Click on the closest city to find more detailed information on a research study in your area.
Arizona
Pheonix : Maricopa Integrated Health System
Anti-TF Antibody (ALT-836) to Treat Septic Patients With Acute Lung Injury or Acute Respiratory Distress Syndrome
California
Los Angeles : Los Angeles County and USC Medical Center
Anti-TF Antibody (ALT-836) to Treat Septic Patients With Acute Lung Injury or Acute Respiratory Distress Syndrome
Sacramento : UC Davis Medical Center
Anti-TF Antibody (ALT-836) to Treat Septic Patients With Acute Lung Injury or Acute Respiratory Distress Syndrome
Stanford : Stanford University
Anti-TF Antibody (ALT-836) to Treat Septic Patients With Acute Lung Injury or Acute Respiratory Distress Syndrome
Colorado
Denver : University of Colorado / National Jewish Health
Study of Ganciclovir/Valganciclovir for Prevention of Cytomegalovirus Reactivation in Acute Injury of the Lung
Connecticut
New Haven : Yale University
Anti-TF Antibody (ALT-836) to Treat Septic Patients With Acute Lung Injury or Acute Respiratory Distress Syndrome
Illinois
Chicago : Northwestern University
Anti-TF Antibody (ALT-836) to Treat Septic Patients With Acute Lung Injury or Acute Respiratory Distress Syndrome
Oak Park : West Suburban Hospital Medical Center
Anti-TF Antibody (ALT-836) to Treat Septic Patients With Acute Lung Injury or Acute Respiratory Distress Syndrome
Peoria : Illinois Lung and Critical Care Institute
Anti-TF Antibody (ALT-836) to Treat Septic Patients With Acute Lung Injury or Acute Respiratory Distress Syndrome
Iowa
Iowa City : University of Iowa
Anti-TF Antibody (ALT-836) to Treat Septic Patients With Acute Lung Injury or Acute Respiratory Distress Syndrome
Kentucky
Hazard : Kentucky Lung Clinic
Anti-TF Antibody (ALT-836) to Treat Septic Patients With Acute Lung Injury or Acute Respiratory Distress Syndrome
Lexington : GSK Investigational Site
SB-681323 IV for Subjects at Risk of Acute Lung Injury or ARDS
Louisville : University of Louisville-Division of Pulmonary and Critical Care
Anti-TF Antibody (ALT-836) to Treat Septic Patients With Acute Lung Injury or Acute Respiratory Distress Syndrome
Massachusetts
Springfield : Baystate Medical Center
Anti-TF Antibody (ALT-836) to Treat Septic Patients With Acute Lung Injury or Acute Respiratory Distress Syndrome
Springfield : Baystate Critical Care Medicine / Tufts University School of Medicine
Study of Ganciclovir/Valganciclovir for Prevention of Cytomegalovirus Reactivation in Acute Injury of the Lung
Michigan
Ann Arbor : University of Michigan
Study of Ganciclovir/Valganciclovir for Prevention of Cytomegalovirus Reactivation in Acute Injury of the Lung
Missouri
Kansas City : Saint Luke's Hospital
Anti-TF Antibody (ALT-836) to Treat Septic Patients With Acute Lung Injury or Acute Respiratory Distress Syndrome
St. Louis : Saint Louis University
Anti-TF Antibody (ALT-836) to Treat Septic Patients With Acute Lung Injury or Acute Respiratory Distress Syndrome
St. Louis : St. John's Mercy Medical Center
Anti-TF Antibody (ALT-836) to Treat Septic Patients With Acute Lung Injury or Acute Respiratory Distress Syndrome
New York
New York : Memorial Sloan-Kettering Cancer Center
Anti-TF Antibody (ALT-836) to Treat Septic Patients With Acute Lung Injury or Acute Respiratory Distress Syndrome
New York City : Mount Sinai Medical Center
Anti-TF Antibody (ALT-836) to Treat Septic Patients With Acute Lung Injury or Acute Respiratory Distress Syndrome
North Carolina
Charlotte : Carolinas Medical Center
Anti-TF Antibody (ALT-836) to Treat Septic Patients With Acute Lung Injury or Acute Respiratory Distress Syndrome
Durham : GSK Investigational Site
SB-681323 IV for Subjects at Risk of Acute Lung Injury or ARDS
Greensboro : Piedmont Respiratory Research Foundation
Anti-TF Antibody (ALT-836) to Treat Septic Patients With Acute Lung Injury or Acute Respiratory Distress Syndrome
Winston-Salem : Wake Forest University
Anti-TF Antibody (ALT-836) to Treat Septic Patients With Acute Lung Injury or Acute Respiratory Distress Syndrome
Winston-Salem : Wakeforest University, School of Medicine
Study of Ganciclovir/Valganciclovir for Prevention of Cytomegalovirus Reactivation in Acute Injury of the Lung
Ohio
Columbus : Ohio State University Medical Center
Study of Ganciclovir/Valganciclovir for Prevention of Cytomegalovirus Reactivation in Acute Injury of the Lung
Oklahoma
Oklahoma City : University of Oklahoma
Anti-TF Antibody (ALT-836) to Treat Septic Patients With Acute Lung Injury or Acute Respiratory Distress Syndrome
Oklahoma City : OU Medical Center
Iloprost Effects on Gas Exchange and Pulmonary Mechanics
Pennsylvania
Philadelphia : GSK Investigational Site
SB-681323 IV for Subjects at Risk of Acute Lung Injury or ARDS
Philadelphia : University of Pennsylvania Medical Center
Study of Ganciclovir/Valganciclovir for Prevention of Cytomegalovirus Reactivation in Acute Injury of the Lung
Pittsburgh : GSK Investigational Site
SB-681323 IV for Subjects at Risk of Acute Lung Injury or ARDS
Pittsburgh : University of Pittsburgh Medical Center
Study of Ganciclovir/Valganciclovir for Prevention of Cytomegalovirus Reactivation in Acute Injury of the Lung
Tennessee
Nashville : GSK Investigational Site
SB-681323 IV for Subjects at Risk of Acute Lung Injury or ARDS
Texas
Houston : Baylor College of Medicine
Anti-TF Antibody (ALT-836) to Treat Septic Patients With Acute Lung Injury or Acute Respiratory Distress Syndrome
Vermont
Burlington : University of Vermont College of Medicine
Study of Ganciclovir/Valganciclovir for Prevention of Cytomegalovirus Reactivation in Acute Injury of the Lung
Canada
Toronto : Sunnybrook Health Sciences Centre
Study of Ganciclovir/Valganciclovir for Prevention of Cytomegalovirus Reactivation in Acute Injury of the Lung
United Kingdom
Harrow : GSK Investigational Site
Safety Study of GSK1995057 Given as Single and Repeat Intravenous Doses in Healthy Subjects.
